Gilead Sciences, Inc.

Good afternoon, everyone, and welcome to Gilead's second quarter 2026 earnings conference call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared remarks, followed by our Q&A session. To ask a question, please press star 1, and to withdraw your question, press star 1 again. Now, I'll hand the call over to Jacquie Ross, Senior Vice President, Treasurer, and Head of Investor Relations.

Thank you, Rebecca. Just after market closed today, we issued a press release with earnings results for the second quarter of 2026. The press release, slides, and supplementary data are available on the Investors section of our website at Gilead.com. The speakers on today's call will be our Chairman and Chief Executive Officer, Daniel O'Day, our Chief Commercial and Corporate Affairs Officer, Johanna Mercier, our Chief Medical Officer, Dietmar Berger, and our Chief Financial Officer, Andrew Dickinson. After that, we'll open the call to Q&A, where the team will be joined by Cindy Peretti, the Executive Vice President of KITE. Let me remind you that we will be making forward-looking statements. Please refer to slide two regarding the risks and uncertainties relating to forward-looking statements that could cause actual results to differ materially. With that, I'll turn the call over to Dan.

Thank you, Jacquie, and thanks, everyone, for joining us on today's call. As you'll see from today's results, Gilead has delivered another quarter of commercial excellence with base business sales up 10% year-over-year, our strongest second quarter growth in three years, driven by our HIV portfolio, Tredelvi, and Livdelzi. This was also an exciting quarter of clinical execution with positive updates across our core therapeutic areas. Turning to HIV performance this quarter, sales grew 12% year-over-year, driven by impressive Bictarvy and PrEP business growth. Yes2Go has quickly become the leading long-acting PrEP option for new patient starts. Quarterly PrEP sales doubled year-over-year, exceeding $1 billion for the first time. With a $4 billion annual run rate for our PrEP business and Bictarvy's continued strength, we are raising our full-year HIV growth expectations to 9% to 10% year-over-year from prior guidance of 8% growth. We continue to advance our extensive HIV pipeline with potential new daily, weekly, monthly, twice yearly, and yearly options. Later this month, we expect an FDA decision on our once daily oral treatment combining Bictegravir and Lenacapavir. BicLen has the potential to become the first dedicated switch regimen within our treatment portfolio. expanding the options we offer for virally suppressed people with HIV and further strengthening our leadership in the switch market. We share detailed data from our positive phase three island one and island two studies at the 2026 International AIDS Society meeting. These data are expected to support the filing and potential launch of the first once-weekly oral HIV treatment regimen, Islatravir plus Lenacapavir, in 2027. In oncology, Tredelvi sales were up 26% year-over-year, reflecting strong demand across both triple-negative and pretreated HR-positive HER2-negative metastatic breast cancer. We also secured additional approvals for Tredelvi this quarter in first-line metastatic triple-negative breast cancer across PD-L1 status. The acquisition of Tubulus has now closed, providing Gilead with an industry-leading ADC platform and Promising Clinical Stage ADCs. At ASCO, we have shared encouraging Phase I efficacy and safety data for GS8824, formerly known as TUB40, in platinum-resistant ovarian cancer. In cell therapy, launch preparations are fully underway for a NitoCell with just five months to go until the PDUFA date. The completed acquisition of Arcelex has given us full ownership of a NitoCell enabling faster, more focused execution in multiple myeloma, as well as the D-domain binder platform for future opportunities in both autologous and in vivo CAR-T. This was a strong quarter for our liver disease business, with Levdelzi sales more than doubling year over year. Levdelzi continues to gain momentum as the leading second-line treatment for primary biliary cholangitis, or PBC. The recent positive Phase III ideal data further strengthened the opportunity for Levdelzi to reach more patients with PBC. We also launched Tepcludex in the U.S. this quarter as the first and only FDA-approved treatment for chronic hepatitis delta virus, or HDV. In summary, it's been a very strong first half and second quarter with impressive revenue growth across therapeutic areas Two commercial launches and three positive phase three readouts. In the second half, we expect another two commercial launches in HIV and oncology while continuing to deliver clinical and commercial excellence across the portfolio. With that, I'll hand it over to Johanna.